Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius    FRE   DE0005785604

FRESENIUS (FRE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Expects to Miss 2020 Targets on Revised 2019 Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 08:32am CET

By Patrick Costello

Fresenius adjusted its mid-term guidance late on Thursday, saying the company no longer expects to meet group targets for 2020 after updating its forecast for next year.

The German health-care company said it expects to see mid-single-digit organic sales growth for 2019, with net income remaining "broadly stable" from 2018.

The company's previously expected group sales to increase at a compounded annual growth rate of 7.1% to 10.3% through 2020, with group net income increasing at a CAGR of 8.3% to 12.6%.

Fresenius said it expects to generate sustainable organic sales growth in the mid-single-digit range from 2020 onward, with group net income expected to grow faster than sales on an organic basis.

Among the group's individual units, Fresenius Medical Care--a provider of dialysis products and services--should generate sales growth and net income in 2019 in line with the levels recorded in 2018, the company said.

It forecasts that the Fresenius Kabi division--an essential drugs and medical device supplier--will deliver mid-single-digit organic sales growth and "low- to mid-single-digit" growth in earnings before interest and taxes next year.

Fresenius Helios, the group's hospital operator unit, expects EBIT to contract at a low- to mid-single digit rate next year, as growth in Spain will be unlikely to offset "headwinds" in Germany resulting from regulatory changes, Fresenius SE said.

The group said it expects to propose a dividend increase for 2018 in line with earnings growth, as well as a further dividend increase in 2019.

The company will release detailed financial guidance for 2019 and on its mid-term targets alongside full-year results for 2018 on Feb. 20.

Write to Patrick Costello at patrick.costello@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS 1.55% 42.01 Delayed Quote.-35.44%
FRESENIUS MEDICAL CARE -2.12% 60.16 Delayed Quote.-31.47%
FRESENIUS SE & CO KGAA --End-of-day quote.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS
12/14FRESENIUS : wins award for compensatory time account calculator
PU
12/12FRESENIUS SE & CO. KGAA : Notification and public disclosure of transactions by ..
EQ
12/11FRESENIUS : UKEF and VAMED agree framework to boost UK healthcare exports
AQ
12/11BASF cuts outlook, now sees profits falling 15-20 percent in 2018
RE
12/10EUROPE MARKETS: European Stocks End Sharply Lower As Data Add To Worries Abou..
DJ
12/10FRESENIUS : UKEF and VAMED agree framework to boost UK healthcare exports
AQ
12/10FRESENIUS SE & CO. KGAA : Notification and public disclosure of transactions by ..
EQ
12/07Akorn CEO Retires Following Court Ruling
DJ
12/07FRESENIUS : Delaware Supreme Court upholds Fresenius' termination of merger agre..
PU
12/07FRESENIUS : Delaware Supreme Court Upholds Fresenius' Termination Of Merger Agre..
DJ
More news
Financials (€)
Sales 2018 33 498 M
EBIT 2018 4 964 M
Net income 2018 2 026 M
Debt 2018 15 866 M
Yield 2018 1,88%
P/E ratio 2018 11,85
P/E ratio 2019 11,72
EV / Sales 2018 1,17x
EV / Sales 2019 1,08x
Capitalization 23 367 M
Chart FRESENIUS
Duration : Period :
Fresenius Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 63,3 €
Spread / Average Target 51%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
FRESENIUS-35.44%26 421
BANGKOK DUSIT MEDICAL SERVICES PCL--.--%12 558
IHH HEALTHCARE BHD--.--%11 040
AIER EYE HOSPITAL GROUP CO LTD--.--%10 461
RAMSAY HEALTH CARE LIMITED-22.43%7 896
PREMIER INC29.91%5 263